Member Info for Laura2022

Superb everyone

O 8p to 4p in 2 days

These small caps should never have been lowly valued at below £1mlnin first place

Plenty more like tjis

Strange first post in over 18mths

Trench HNY

I assume the greenboxes means they didnt get a new life

Good morning and HNY to all

Down to just 1.5mln on ask, much improved from the 7mln last week

Here's to 2026 genuine investors

Still building here from below 13p

Hny all

Record revenues for year ended June 2025

* record order book

* Recently booked a further amount of revenues for contracts to be completed Dec 2025

*recently awarded options at 40:, 170% and 350% premiums to current share price , with focus on next step for company of "cash generation "

Key growth in all areas , particularly bio statistics, company very pleased and very confident about the niche growth markets many of which are now mandatory under EU law and most could well become mandatory for drug design. Positive regulatory environment eg FDA

[ ] Key market drivers

* model informed discovery/bio stats help

> costs $2.5bln and 10-15yrs to get drug to market and less than 5% success rate - PYC modelling drastically cuts this and using MMID/BS can

1) save $100-500mln

2) increase to 20-30% success at Phase II

3) 30-50% fewer patients

[ ] Key growth/CAGR markets which PYC operate

MMID 18% CAGR with market set to be $13bln

Bio Statistics 24% CAGR $40bln market

Bmeister

Morning

What a move, kike you said on PYC.these undervalued smal caps can move amazingly

What a move

Happy new year

As you can see by my reply, its all relative and whilst all are loss making PYC is clearly hugely undervalued on peer/sector average.

PYC in 2025 grew revenues , reduced losses and now talk of "cash generation " and have ambitious options for new senior personnel

Best wishes

Well done on MBO BTW

2025 saw 3 or 4 posters intent on disruption, hopefully new y ear resolutions were embarked upon

Thanks marco

Would expect a TR1 after NY

Thanks ChrisHutch

You enjoy

...

Peer comparisons on revenue v mkt cap

APTA £35mln cap and £1.2mln full year revs( = x 30 annual rev)

FAB £17 mln and £1.96mln full year  and recently reported reduced  revenues for H1 ( x 9)

Some commentary has suggested 100p for FAB which puts its at x90

PYC £0.85mln  and £0.85mln full year which was 40% growth ( x 1)

GENI (£10mln) revenues £1.6mln, losses £2.4

2yr highs and nearly 200% up for many including rivaldo,Mp and myself

Just 2.5mln left now

Nice buy at full ask

How can PYC bw valued at same as last years full revenues (c£850,000)

A company on AIM just reported just £375k half year revs and valued at £20mln!

Sector average is at least x 10 annual revenues (most in PYC sector at x 15+)

PYC is coming for breakeven and "cash generation ",

Will soon be waking up to mews on:

Dosemerx Jv

Further biostatistics contracts

Further core contracts

Further patient recruitment

As opposed to green boxes

Hopefully 2026 will see more harmony

Hny

Thanks for this excellent link and HNY rivaldo

As.far as I'm aware no other posters on investments i hold (over 20) go to other boards for prolonged periods (12mths ) with the sole intention of disrupting, arguing , and antagonising

No one on here go to other boards and disrupt , most LSE users co exist congenially..for some reason 3 oe 4 people cant manage this which says everything about them

And also it clearly states to help create shareholder value and as company moves to "cash generation", the contracts for bio statistics are by their nature likely to be much higher too ( mentioned in the Q and A)

So clearly bio statistics (being regulatory driven in most major economies) is seen as.a huge asset

I really dont underhand why people skirt over issues with their own companies but then fixate here , its really really odd

Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under the Company's existing share option scheme (the "Scheme"):

1. 1,516,044 Options with an exercise price of 0.41 pence, representing a 41% premium to the closing mid-market price per Ordinary Share on 22 December 2025. All these Options vest on the first anniversary of Mr Thissen's employment, being 1 July 2026.

2. 1,516,044 Options with exercise price of 0.79 pence, representing a 172% premium to the closing mid-market price per Ordinary Share on 22 December 2025.

3. 1,516,044 Options with an exercise price of 1.29 pence, representing a 345% premium to